RHYTHM PHARMACEUTICALS, INC. Debt Securities, Available-for-sale
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Debt Securities, Available-for-sale of $265.28 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale $265.28M.
- 2026-03-31: Debt Securities, Available-for-sale $278.49M.
- 2025-12-31: Debt Securities, Available-for-sale $334.65M.
- 2025-09-30: Debt Securities, Available-for-sale $363.98M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $265.28M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $278.49M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $334.65M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $363.98M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $155.44M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $208.39M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $231.43M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $250.87M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $157.46M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $147.77M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $215.76M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $234.67M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $137.92M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $184.92M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $205.61M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $162.71M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $122.39M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $162.43M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $235.61M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $235.98M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $298.81M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $317.48M 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $71.94M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $134.11M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $169.53M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $201.65M 10-Q · filed 2020-05-04 | |
| 2019-12-31 | $230.16M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $90.75M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $132.05M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $179.42M 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $202.52M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $214.22M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $77.17M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $93.51M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $113.85M 10-K · filed 2019-03-08 | $113.99M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |